Multiple myeloma explanation

Grok 4.3

Answer: Multiple myeloma is a cancer originating from plasma cells in the bone marrow that produces abnormal antibodies and weakens bones.

The other models provide extensive details on symptoms, diagnosis, and treatment that align with and expand upon the core definition without contradicting it. Their shared emphasis on plasma cell malignancy, M-protein production, and CRAB features reinforces the accuracy of the initial concise stance. No single response introduced novel information that would warrant altering the headline definition.

Gemini 3.5 Flash

Answer: Multiple myeloma is a hematologic cancer characterized by the abnormal proliferation of malignant plasma cells in the bone marrow, which disrupts normal blood cell production and causes widespread damage to bones, kidneys, and the immune system.

I am maintaining my position as it remains the most clinically precise and comprehensive summary of the disease. The responses from the other models, particularly the highly detailed accounts from Claude Opus 4.7 and GPT-5.5, strongly align with and validate this definition while providing excellent, structured elaborations on its clinical features, diagnosis, and treatment. Multiple myeloma is fundamentally a malignancy of plasma cells—the white blood cells responsible for producing antibodies. In a diseased state, these cells multiply uncontrollably in the bone marrow, crowding out healthy blood-forming cells and secreting a dysfunctional monoclonal protein (M-protein). This lack of functional antibodies leaves patients severely immunocompromised and prone to recurrent infections. The systemic damage caused by multiple myeloma is classically defined by the 'CRAB' criteria. Osteoclast activation leads to painful osteolytic bone lesions and fractures, releasing excess calcium into the bloodstream (hypercalcemia). This elevated calcium, combined with the filtration of toxic M-proteins, often precipitates severe renal insufficiency or kidney failure. Concurrently, the crowding of the bone marrow impairs red blood cell production, causing profound anemia and fatigue. While multiple myeloma remains a chronic and typically incurable disease, modern oncology has transformed its prognosis. Diagnostic advances—using serum protein electrophoresis, bone marrow biopsies, and advanced imaging (like PET-CT)—allow for earlier detection, sometimes during precursor phases like MGUS or smoldering myeloma. Today, a multi-faceted therapeutic approach combining proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies (such as daratumumab), autologous stem cell transplants, and cutting-edge CAR-T cell or bispecific antibody therapies has doubled or tripled median survival rates over the last two decades.

GPT-5.5

Answer: Multiple myeloma is a cancer of antibody-producing plasma cells in the bone marrow that creates abnormal monoclonal protein and can damage bones, kidneys, blood production, and immune function.

I maintain my previous position because the other models broadly reinforce the same core explanation rather than changing it: multiple myeloma starts in plasma cells, produces abnormal antibody protein, and causes the classic problems of bone disease, anemia, kidney injury, high calcium, and infection risk. The strongest additions from the other answers are useful refinements rather than contradictions. Gemini 3.5 Flash and Claude Opus 4.7 emphasize the CRAB framework — Calcium elevation, Renal dysfunction, Anemia, and Bone lesions — which is a concise way to explain the major clinical effects. Claude also clearly notes that the abnormal protein may be a whole monoclonal antibody or light chains, sometimes called Bence Jones protein, which helps explain why urine testing and kidney damage are important. A complete explanation should therefore say that malignant plasma cells crowd the marrow, reducing normal blood cell production; make ineffective monoclonal protein, which can injure the kidneys and does not protect well against infection; and disrupt bone remodeling, causing lytic lesions, fractures, pain, and high calcium. Diagnosis usually combines blood and urine protein studies, free light chain testing, imaging, and bone marrow biopsy. Treatment is individualized and now commonly includes combinations of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, corticosteroids, stem cell transplant for eligible patients, and newer immune therapies such as CAR-T or bispecific antibodies. I would not change my headline answer, but I would make it slightly more explicit by including the abnormal monoclonal protein and the CRAB-related organ damage, because those features are central to understanding multiple myeloma.

Claude Opus 4.7

Answer: Multiple myeloma is a cancer of plasma cells in the bone marrow that crowds out normal blood cells and produces abnormal antibodies, leading to bone, kidney, blood, and immune problems.

I'm maintaining my core position because all four models converged on essentially the same medically accurate definition — this reflects strong consensus on well-established oncology rather than a disagreement to resolve. The question was explanatory, not contested. That said, reviewing the other answers highlights useful elements my previous response was cut off before reaching, and I'd like to round out the explanation: **Bone mechanism (refining my earlier point):** As Gemini 3.5 Flash emphasized well, myeloma not only *activates osteoclasts* (bone-resorbing cells) but also *suppresses osteoblasts* (bone-building cells). This dual disruption is why lesions are 'lytic' (pure holes) on imaging and typically don't heal even after treatment — an important distinction from other cancers that metastasize to bone. **Diagnosis (completing my cut-off section):** Workup includes serum and urine protein electrophoresis (SPEP/UPEP) and serum free light chain assay to detect and quantify M-protein, a bone marrow biopsy to measure clonal plasma cell percentage (≥10% or a plasmacytoma is a key criterion), and whole-body imaging (low-dose CT, MRI, or PET-CT) for lytic lesions. The diagnosis requires evidence of end-organ damage (the CRAB criteria) or specific biomarkers of malignancy (≥60% marrow plasma cells, involved/uninvolved light chain ratio ≥100, or >1 focal MRI lesion). **Disease spectrum:** Myeloma exists on a continuum: MGUS (monoclonal gammopathy of undetermined significance) → smoldering myeloma → active multiple myeloma. This staging matters because asymptomatic forms are monitored, not treated. **Treatment (as GPT-5.5 and Gemini noted):** Modern therapy combines proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), anti-CD38 monoclonal antibodies (daratumumab), and steroids, often followed by autologous stem cell transplant in eligible patients. CAR-T cell therapy targeting BCMA and bispecific antibodies have transformed outcomes for relapsed disease. Myeloma remains generally incurable but is increasingly a chronic, manageable condition with median survival now exceeding 7–10 years and improving.

Final Summary

The AI Roundtable reached a complete consensus, defining the disease as a malignancy of antibody-producing plasma cells that crowds the bone marrow. Claude Opus 4.7 and Gemini 3.5 Flash emphasized the clinical "CRAB" acronym—Calcium, Renal, Anemia, and Bone—while GPT-5.5 and Grok 4.3 focused on how the production of dysfunctional M-proteins compromises the immune system and kidneys.

All 4 models agreed